UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

Dated March 2, 2017

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant's Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant's principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☒ No ☐

This Form 6-K is hereby filed and incorporated by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 2, 2017.

Aurinia Pharmaceuticals Inc.

By: /s/ Dennis Bourgeault
Name: Dennis Bourgeault
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit	**Description of Exhibit**
99.1	Material Change Report dated March 2, 2017

Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as an exhibit to the Registrant's Registration Statement on Form F-10 (File No. 333-206994), as amended or supplemented.

Exhibit 99.1

FORM 51-102F3

MATERIAL CHANGE REPORT

ITEM 1. ***Name and Address of Company***

Aurinia Pharmaceuticals Inc. (the "**Company**")
1203 – 4464 Markham Street
Victoria, BC V8Z 7X8

ITEM 2. ***Date of Material Change***

March 1, 2017

ITEM 3. ***News Release***

A news release relating to the material change described herein was disseminated on March 1, 2017 via Business Wire.

ITEM 4. ***Summary of Material Change***

The Company announced top-line results from its Phase 2b AURA-LV study in lupus nephritis ("**LN**").

ITEM 5. ***Full Description of Material Change***

The Company announced top-line results from our Phase 2b AURA-LV (AURA) study in LN. At 48 weeks, the trial met the complete and partial remission ("CR"/ "PR") endpoints, demonstrating statistically significantly greater CR and PR in patients in both low dose (23.7mg of voclosporin twice daily (p<.001)) and high dose (39.5mg twice daily (p=.026)) cohorts versus the control group.

Each arm of the study included the current standard of care of mycophenolate mofetil as background therapy and a forced steroid taper to 5mg/day by week 8 and 2.5mg by week 16. No unexpected safety signals were observed and there were no additional deaths in the voclosporin treated patients; however, there were three deaths and one malignancy reported in the control arm after completion of the study treatment period.

The 24 and 48-week top-line efficacy results are summarized below:

Endpoint	**Treatment**	**24 weeks**	**Odds ratio**	**P-value***	**48 weeks**	**Odds Ratio**	**P-value***
Complete Remission	23.7mg VCS BID	33%	2.03	p=.045	49%	3.21	**p<.001**
	39.5mg VCS BID	27%	1.59	p=.204	40%	2.10	**p=.026**
	Control Arm	19%	*NA*	*NA*	24%	*NA*	*NA*
Partial Remission	23.7mg VCS BID	70%	2.33	p=.007	68%	2.34	**p=.007**
	39.5mg VCS BID	66%	2.03	p=.024	72%	2.68	**p=.002**
	Control Arm	49%	*NA*	*NA*	48%	*NA*	*NA*

**All p-values are vs control*

ITEM 5.2. ***Disclosure of Restructuring Transactions***

Not applicable.

ITEM 6. ***Reliance on Subsection 7.1(2) of National Instrument 51-102***

Not applicable.

ITEM 7. ***Omitted Information***

There are no significant facts required to be disclosed herein which have been omitted.

ITEM 8. ***Executive Officer***

For further information, please contact:

Michael R. Martin, Chief Operating Officer
250-415-9713
mmartin@auriniapharma.com

ITEM 9. ***Date of Report***

March 2, 2017